Status:
COMPLETED
Characterization of the Immunological Profile Patients With Post-polio Syndrome
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Poliomyelitis Sequelae
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Many patients with polio sequelae have persistent and progressive worsening more than 15 years after the initial damage, with loss of muscle strength, asthenia and musculoskeletal pain. In these patie...
Eligibility Criteria
Inclusion
- Subjects with Post-polio Syndrome :
- age ≥ 18 years
- meeting the definition of the SPP according to the criteria of Halstead et al. (1995)
- Controlled subjects :
- age ≥ 18 years
- matched on sex and age (+/- 5 years) with subjects with PPS
Exclusion
- intercurrent neurological pathology,
- uncontrolled cardiovascular risk factors
- pulmonary comorbidity
- endocrine disorders
- systemic inflammatory pathology, autoimmune disease, dry syndrome,
- renal failure
- anti-inflammatory treatment in progress or in the previous month, or immunoregulatory aim whatever its nature,
- patients with SPP who received polyvalent IV immunoglobulins in the 3 years prior to inclusion, or taking anticoagulants
Key Trial Info
Start Date :
December 6 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 22 2020
Estimated Enrollment :
73 Patients enrolled
Trial Details
Trial ID
NCT03396783
Start Date
December 6 2017
End Date
February 22 2020
Last Update
December 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU Lapeyronie
Montpellier, Herault, France, 34295